Preventing Medication Errors for Hospitalized People with Parkinson’s Disease – Results of Six Months of Proactive Intervention
Objective: To determine whether a Parkinson’s disease (PD) Inpatient Program will prevent medication errors and ultimately improve the safety and quality of care for hospitalized…Can We Rid Uganda of the Societal Myth That Parkinson’s Disease Is Witchcraft?
Objective: Educate rural Ugandans that Parkinson’s Disease (PD) is a scientific disorder, not contagious or the result of anything mystical Background: People with PD (PWP)…Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study
Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…Combining alpha-synuclein PET and seeded amplification assays to improve the diagnostic accuracy of Multiple System Atrophy of the Parkinsonian subtype (MSA-P)
Objective: To determine whether the combination of spatial (PET [18F]ACI-12589) and conformational (skin seed amplification assay; SAA) a-syn data aids the early differential diagnosis of…Is cathepsin D a good target for therapy in Tau-related conditions?
Objective: To study the involvement of cathepsin D in the pathogenesis of Tau-related conditions. Background: The endo-lysosomal system (ELS) is central in processing of neurodegenerative…Identification of underlying Lewy body pathology in primary tauopathies by α-synuclein seed amplification assay
Objective: To determine intravitam prevalence of α-synuclein (αSyn) pathology in primary tauopathies, such as PSP and CBS, by αSyn seed amplification assay (synSAA) Background: Neuropathological…Early Syndromes and Clinicopathologic Progression in Progressive Supranuclear Palsy
Objective: We aimed to characterize early clinical features of progressive supranuclear palsy (PSP) that might correlate with clinical course and neuropathologic findings. Background: Progressive supranuclear…18F-Florzolotau PET uncovers the Co-pathological Heterogeneity of Tau Protein in Dementia with Lewy Bodies
Objective: We attempted to reveal the topographical deposition patterns of tau proteins in the living brains of patients with DLB in vivo by virtue of…Passive smartphone speech monitoring in isolated rapid eye movement sleep behaviour disorder
Objective: We aimed to design and test the sensitivity of a fully-automated and noise-resistant smartphone-based system that can unobtrusively screen for prodromal parkinsonian speech disorder…Beyond Clinical Presentation: Incorporating Neuroimaging and Biofluid Markers to Predict Progression of Parkinson’s Disease
Objective: To assess whether including measurements of neuroimaging and biofluid-based biomarkers improves predictive ability of models of motor and non-motor progression up to 5-year follow-up…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 181
- Next Page »